Patent ID: 11878052
Assignee: LENTIGEN TECHNOLOGY, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 11:
12. The CAR of claim 11, wherein the at least one transmembrane domain comprises a transmembrane domain of a protein selected from the group consisting of the alpha chain of a T-cell receptor, the beta chain of a T-cell receptor, the zeta chain of a T-cell receptor, a CD8, a CD28, a CD3 epsilon, a CD45, a CD4, a CD5, a CD9, a CD16, a CD22, a CD33, a CD37, a CD64, a CD80, a CD83, a CD86, a CD134, a CD137, a CD 154, and a TNFRSF19.